Back

Vitamin D as an add-on therapy to phosphodiesterase-5 inhibitor in experimental pulmonary arterial hypertension

19 May 2025 (15:51 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in basic science (3) Drugs, Drug Targets HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rui Miguel Da Costa Adao

Complutense University of Madrid, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail
Relationship of biomarkers and whole-heart myocardial mechanics in patients with non-ischemic dilated cardiomyopathy
Ms G. Jakuskaite (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Dampening pyruvate to succinate conversion during early reperfusion via mitofusin1 induced mitochondrial hibernation reduces mitochondrial burnout and myocardial reperfusion injury
Doctor Y. Li (Sha Tin, HK)
Abstract Slides Video
Presentation thumbnail
Plasma from endometriosis patients and endometriosis tissue-derived pro-inflammatory cytokines promote endothelial dysfunction through activation of the AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway
Doctor A. Mroueh (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Mitochondrial nanotunneling mediates intermitochondrial communication during cardiac ischemia and reperfusion to dictate function and fate
Miss Q. GU (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
12 month kinetic of fibrosis assessed with cardiac magnetic resonance in dilated cardiomyopathy patients with different etiology
Doctor S. Wisniowska-Smialek (Krakow, PL)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in basic science (3)

The Event

Event poster

Heart Failure 2025

19 May 2025 15:51 CET
You may be interested in
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
thumbnail
Congress Session
Paradigm change in pulmonary hypertension: from bench to bedside
thumbnail
Congress Presentation
Pulmonary artery denervation accoss the spectrum of different aetiologies of pulmonary hypertension: the current evidence and future perspective

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources